Tag: ATI-0918

Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin

Cytori Therapeutics (Nasdaq:CYTX) provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product....

Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results

Cytori Therapeutics (NASDAQ:CYTX) announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical...

Cytori Announces Proposed Public Offering of Common Stock

Cytori Therapeutics announced it plans to offer a public offering of common stock in order to fund the HABEO and...